From: Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
Author - Year | Pre stimulaiton | Cell culture | IC | Starting material | Culture system | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medium | Stimulation | Serum and supplements | Source | Inoculation [cells/reactor] | Volume [mL] | Reactor | Fibers | Cut off [kDa] | Surface area [cm2] | Perfusion flow [mL/min] | Control | |||
T cells | ||||||||||||||
 Lamers [124] - 1994 | IL2, PHA or CD3 mAb | AIMV | IL2 | 10% AB | Glutamine and glucose + RPMI | PBMC | 109 | NP | Immuno*star 4000 | 10,000 | 10 | NP | 50 | Control glucose at 1.5 g/L |
 Lamers [125] - 1999 | IL2, PHA | AIMV | IL2 | NP | Glutamine and glucose + RPMI | PBMC | 1.7–3.1 × 108 | 100 | Immuno*star 4000 | 10,000 | 10 | NP | 50 | Control glucose at 2 g/l; control lactate levels |
 Liu [126] - 1999 | Anti CD3/CD8 mAb | CCM | IL2 | 1% AB | Medium | CD4+ and CD8+ from PBMC | 2–8 × 107 | NP | Cellco Cellmax | NP | NP | NP | NP | Control glucose at 50–100 mg/dL |
 Trickett [127] - 2002 | IL2, Anti CD3 or PHA | AIMV | CD3/CD28 beads or PHA | 5 to 2% FBS | Medium | HIV infected CD4+ cells from PBMC | 2–3 107 | NP | Cellmax Quad | NP | NP | NP | 50 | Keep glucose above 50% of the baseline value |
 De Bartolo [114] - 2007 | PHA | DMEM | NP | 10% FBS | Medium | PBMC | 8 × 107 | 24 | PEEK-WC-HF | NP | NP | 128 | 5 to 10 | NP |
 Curcio [128] - 2012 | PHA | DMEM | PHA | 10% FBS | Medium | PBMC | 8 × 107 | 25 | Parallel-HFMBR | NP | NP | 128 | 2–10 | Adjust concentrations to number of cells |
 Curcio [128] - 2012 | PHA | DMEM | PHA | 10% FBS | Medium | PBMC | 8 × 107 | 35 | Crossed-HFMBR | NP | NP | NP | 2–10 | Adjust concentrations to number of cells |
 Nankervis [111] - 2018 | IL2, Anti CD3/CD8 beads + IL7 | NP | IL2; IL7 | NP | Cells | PBMC | NP | 100 | Quantum 1st generation protocol | 11,520 | 17 | NP | EC: 100 IC: 1 | NP |
 Nankervis [111] - 2018 | IL2, Anti CD3/CD8 beads | NP | IL2 | NP | Cells | PBMC | NP | 100 | Quantum 2nd generation protocol | 11,520 | 17 | NP | Max. 300 | NP |
 Coeshott [112] - 2019 | IL2, Anti CD3/CD8 beads | PRIME-XV | NP | NP | Cells | PBMC | 3.0–8.5 × 107 | 124 | Quantum | 11,520 | 17 | 21,000 | Max. 300 (IC) | Remove lactate |
TIL | ||||||||||||||
 Knazek [78] - 1990 | IL2, Autol. LAK supern. and serum | AIMV | IL2 OR LAK supernatant. + HS | Glucose and glutamine | Medium | Melanoma | NP | 50 | Cellmax 100 | 8000 |  | 11,000 | 40–300n | Control glucose at 1–1.5 g/L |
 Hillman [115] - 1994 | IL2, TNFa | AIMV | IL2 | 10% AB | RPMI | Kidney tumors | 5–30 × 108 | 30 | IMMUNO*STAR® 1000 Cell Expander | NP | 10 | 3000 | EC: 2 IC: 200 | Control glucose |
 Freedman [119] - 1994 | IL2 | AIMV | IL2 | NP | Medium | Ascites/pleural effusions/solid tumors | 109 | NP | Cellmax 100 | 8000 | 4 | 23,000 | 60–300 | Control glucose |
 Lewko [129] - 1994 | IL2, Autol. LAK supern. and serum | AIMV | IL2 | NP | Medium | Tumor | 1–2 × 109 | NP | Cellmax 100 | NP | 4 | 23,000 | NP | Control glucose between 1.0–1.5 g/L |
 Lewko [117] - 2000 | IL2, Autol. LAK supern. and serum | AIMV | IL2 | NP | Medium | Tumor | 1–2 × 109 | NP | Cellmax 100 | NP | NP | 23,000 | NP | Control glucose between 1.0–1.5 g/L |
 Freedman [130] - 2000 | IL2 | AIMV | IL2 | NP | Medium | Tumor samples | 1–2 × 109 | NP | Cellmax 100 | NP | NP | NP | NP | NP |
 Malone [118] - 2001 | IL2, OKT3 | AIMV | IL2 | Glutamine | Medium | Tumor samples | 4–6 × 108 | 100 | Celco - not specified | NP | 30–150 | 2200 | NP | Keep lactate below 1000 units/mL |
PBL | ||||||||||||||
 Pan [120] - 1999 | IL2, OKT3 | AIMV | IL2 | 5% FBS, glutamine | Medium | PBL | 5–9.3 × 107 | NP | Cellmax Quad pump station | NP | NP | NP | NP | Controlling lactate levels |
 Shankar [121] - 1997 | OKT3 | AIMV | IL2 | 5% FBS, glutamine | Medium | PBL | 5 × 107 | 11.4 | Cellmax Artificial Capillary | NP | NP | NP | NP | Keep lactate below 0.5 mg/mL |
 Stroncek [122] - 1999 | OKT3 | AIMV | IL2 | 5% FBS, glutamine | Medium | PBL | 108 | 11 | Cellmax Artificial Capillary | NP | NP | NP | NP | NP |